IPO Update: Three Biopharma Offerings In January Contrast With Last Year’s Slow Start

AnaptysBio, Jounce and ObsEva were the first three companies to go public in 2017 – all in January – while no therapeutics firms went public in January 2016. The difference? Better US biopharma stock performance.

stock

Three biopharmaceutical companies launched US initial public offerings in January, kicking off 2017 with more confidence than drug developers showed in 2016 when there were no biopharma IPOs during the first month of the year.

With the AnaptysBio Inc., Jounce Therapeutics Inc. and ObsEva SA offerings in January, 2017 is a bit ahead of 2016, which had 30 biopharma IPOs – an...

More from Business

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By 

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.